Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
02
2019
accepted:
31
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
4
3
2020
Statut:
epublish
Résumé
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenged by the absence of accurate early diagnostic and prognostic biomarkers. CA19-9 is the established, diagnostic tumour marker in PDAC, despite its limitations. Effective primary screening using circulating biomarker panels have only been considered in a handful of studies and we investigated whether combinations of inflammatory cytokines and angiogenic factors in multivariate logistic models could facilitate earlier diagnosis in our South African setting. Plasma levels of 38 cytokines and angiogenic factors were measured in 131 Black South African patients, 85 with PDAC, 25 with benign biliary pathology (BBP) and 21 benign non-HPB controls (BC), by use of human magnetic multiplex screening assays. Multivariate biomarker panels were developed by identifying the top performing biomolecules from univariate logistic regression. Receiver-operator characteristic (ROC) curves and area under the ROC curve (AUC) are reported. Classification modelling to distinguish PDAC patients from BC showed that a panel of CA19-9 and CXCL10 (IP-10) demonstrated improved diagnostic power over CA19-9 alone (AUC = 0.977 vs. AUC = 0.807, p-value = 0.001). A combined panel including age, BMI and IL-15 showed significant diagnostic power in discriminating PDAC from BBP (AUC = 0.952, p < 0.0001). Finally, a combined panel of IL-8, IL-15 and gender demonstrated diagnostic accuracy (AUC = 0.830, p < 0.0001) in distinguishing PDAC in the presence of jaundice from benign controls with either jaundice, choledocholithiasis or common bile duct injury. Combined biomarker panels improve diagnostic accuracy in PDAC. In addition to CA19-9, cytokines CXCL10, IL-8 and IL-15 are strong additions to diagnostic biomarker panels in PDAC in Black South Africans.
Sections du résumé
BACKGROUND
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenged by the absence of accurate early diagnostic and prognostic biomarkers. CA19-9 is the established, diagnostic tumour marker in PDAC, despite its limitations. Effective primary screening using circulating biomarker panels have only been considered in a handful of studies and we investigated whether combinations of inflammatory cytokines and angiogenic factors in multivariate logistic models could facilitate earlier diagnosis in our South African setting.
METHODS
Plasma levels of 38 cytokines and angiogenic factors were measured in 131 Black South African patients, 85 with PDAC, 25 with benign biliary pathology (BBP) and 21 benign non-HPB controls (BC), by use of human magnetic multiplex screening assays. Multivariate biomarker panels were developed by identifying the top performing biomolecules from univariate logistic regression. Receiver-operator characteristic (ROC) curves and area under the ROC curve (AUC) are reported.
RESULTS
Classification modelling to distinguish PDAC patients from BC showed that a panel of CA19-9 and CXCL10 (IP-10) demonstrated improved diagnostic power over CA19-9 alone (AUC = 0.977 vs. AUC = 0.807, p-value = 0.001). A combined panel including age, BMI and IL-15 showed significant diagnostic power in discriminating PDAC from BBP (AUC = 0.952, p < 0.0001). Finally, a combined panel of IL-8, IL-15 and gender demonstrated diagnostic accuracy (AUC = 0.830, p < 0.0001) in distinguishing PDAC in the presence of jaundice from benign controls with either jaundice, choledocholithiasis or common bile duct injury.
CONCLUSIONS
Combined biomarker panels improve diagnostic accuracy in PDAC. In addition to CA19-9, cytokines CXCL10, IL-8 and IL-15 are strong additions to diagnostic biomarker panels in PDAC in Black South Africans.
Identifiants
pubmed: 31415645
doi: 10.1371/journal.pone.0221169
pii: PONE-D-19-03802
pmc: PMC6695103
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221169Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Biosci. 2005 Jan 01;10:853-65
pubmed: 15569594
Cancer Res. 2006 Oct 1;66(19):9509-18
pubmed: 17018607
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12890-5
pubmed: 17652168
Immunol Rev. 2008 Apr;222:357-68
pubmed: 18364014
Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G709-17
pubmed: 18669622
Int J Cancer. 2009 Feb 15;124(4):853-61
pubmed: 19035451
Autoimmun Rev. 2009 Mar;8(5):379-83
pubmed: 19105984
Neoplasia. 2009 May;11(5):497-508
pubmed: 19412434
Biomark Med. 2008 Oct;2(5):447-55
pubmed: 20477422
Anticancer Res. 2010 Jul;30(7):2911-7
pubmed: 20683032
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
BMC Cancer. 2011 Jul 05;11:286
pubmed: 21729304
World J Gastroenterol. 2012 Mar 14;18(10):1123-9
pubmed: 22416189
Oncol Lett. 2011 Jul;2(4):583-589
pubmed: 22848232
Oncologist. 2013;18(5):543-8
pubmed: 23657686
Cancer Treat Rev. 2014 Feb;40(1):118-28
pubmed: 23849556
Front Physiol. 2014 Jan 16;4:415
pubmed: 24474939
Oncoimmunology. 2013 Dec 1;2(12):e26788
pubmed: 24498555
Clin Cancer Res. 2014 Apr 15;20(8):2044-50
pubmed: 24737791
PLoS One. 2014 May 21;9(5):e97613
pubmed: 24849506
Mol Cancer. 2014 May 20;13:114
pubmed: 24884871
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Sci Rep. 2014 Aug 01;4:5911
pubmed: 25081383
World J Gastroenterol. 2014 Aug 28;20(32):11241-8
pubmed: 25170208
Exp Mol Pathol. 2015 Aug;99(1):163-72
pubmed: 26079660
Oncoimmunology. 2015 Apr 2;4(9):e1027473
pubmed: 26405599
Oncol Lett. 2015 Aug;10(2):967-971
pubmed: 26622606
Cancer Lett. 2016 Oct 10;381(1):201-10
pubmed: 26723874
Cancer Biomark. 2016 Mar 11;16(4):545-54
pubmed: 27002757
PLoS One. 2016 May 12;11(5):e0154016
pubmed: 27170998
Pancreatology. 2017 May - Jun;17(3):438-444
pubmed: 28377069
Immunol Lett. 2017 Oct;190:159-168
pubmed: 28823521
Oncotarget. 2017 May 25;8(34):56968-56979
pubmed: 28915646
J Neuroimmunol. 2018 Feb 15;315:15-23
pubmed: 29306400
Sci Rep. 2018 Feb 21;8(1):3383
pubmed: 29467409
Am J Cancer Res. 2018 Mar 01;8(3):332-353
pubmed: 29636993
J Cancer. 2018 Apr 19;9(10):1804-1812
pubmed: 29805707
Eur J Surg Oncol. 2018 Oct;44(10):1619-1623
pubmed: 30146251
World J Gastrointest Oncol. 2018 Aug 15;10(8):202-210
pubmed: 30147846
Int J Cancer. 2019 Apr 15;144(8):1877-1887
pubmed: 30259989